Literature DB >> 12227725

The correction of anemia in severe resistant heart failure with erythropoietin and intravenous iron prevents the progression of both the heart and the renal failure and markedly reduces hospitalization.

D S Silverberg1, D Wexler, M Blum, J Tchebiner, D Sheps, G Keren, D Schwartz, R Baruch, T Yachnin, M Shaked, A Zubkov, S Steinbruch, A Iaina.   

Abstract

Both Congestive Heart Failure (CHF) and Chronic Renal Failure (CRF) are increasing steadily in the community. We propose that there is a vicious circle established whereby CHF and CRF both cause anemia and the anemia then worsens both the CHF and CRF causing more anemia and so on. We call this the Cardio Renal Anemia (CRA) syndrome. By the combination of active treatment of the CHF and control of the anemia with subcutaneous erythropoietin and intravenous iron, the progression of both the CHF and the CRF can be slowed or stopped in most cases, the quality of life improved and the need for recurrent hospitalization reduced. This will involve cooperation between internists, cardiologists, and nephrologists to allow early and maximal therapy of both the CHF and the anemia.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12227725

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  10 in total

1.  Impact of chronic kidney disease and anemia on physical function in patients with chronic heart failure.

Authors:  Masakazu Saitoh; Haruki Itoh; Nobuo Morotomi; Tetsuya Ozawa; Noriko Ishii; Reina Uewaki; Kentaro Hori; Yohei Shiotani; Miki Ando; Shogo Nakashima; Kana Kawai; Azusa Ohno; Masatoshi Nagayama
Journal:  Cardiorenal Med       Date:  2014-04-17       Impact factor: 2.041

Review 2.  Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: Prevention, management during intercurrent illness or acute decompensation, and use of biomarkers.

Authors:  J Malcom O Arnold; Jonathan G Howlett; Paul Dorian; Anique Ducharme; Nadia Giannetti; Haissam Haddad; George A Heckman; Andrew Ignaszewski; Debra Isaac; Philip Jong; Peter Liu; Elizabeth Mann; Robert S McKelvie; Gordon W Moe; John D Parker; Anna M Svendsen; Ross T Tsuyuki; Kelly O'Halloran; Heather J Ross; Vivek Rao; Errol J Sequeira; Michel White
Journal:  Can J Cardiol       Date:  2007-01       Impact factor: 5.223

Review 3.  Anemia and heart failure.

Authors:  Eileen O'Meara; Clare Murphy; John J V McMurray
Journal:  Curr Heart Fail Rep       Date:  2004-12

4.  Prevalence, types, risk factors, and outcomes of cardiorenal syndrome in a rural population of central India: A cross-sectional study.

Authors:  Maria Prothasis; Anuj Varma; Shilpa Gaidhane; Sunil Kumar; Nazli Khatib; Quazi S Zahiruddin; Abhay Gaidhane
Journal:  J Family Med Prim Care       Date:  2020-08-25

5.  The cardiorenal syndrome: a review.

Authors:  B N Shah; K Greaves
Journal:  Int J Nephrol       Date:  2010-12-28

6.  Anemia and chronic kidney disease are associated with poor outcomes in heart failure patients.

Authors:  Jean-Christophe Luthi; W Dana Flanders; Michel Burnier; Bernard Burnand; William M McClellan
Journal:  BMC Nephrol       Date:  2006-03-06       Impact factor: 2.388

7.  Electronically monitored medication adherence predicts hospitalization in heart failure patients.

Authors:  Barbara Riegel; George J Knafl
Journal:  Patient Prefer Adherence       Date:  2013-12-05       Impact factor: 2.711

8.  A Bibliometric and Visualized Analysis of Uremic Cardiomyopathy From 1990 to 2021.

Authors:  Jing-Fu Bao; Pan-Pan Hu; Qin-Ying She; Difei Zhang; Jia-Ju Mo; Aiqing Li
Journal:  Front Cardiovasc Med       Date:  2022-07-12

Review 9.  Science review: recombinant human erythropoietin in critical illness: a role beyond anemia?

Authors:  Thomas Coleman; Michael Brines
Journal:  Crit Care       Date:  2004-06-16       Impact factor: 9.097

Review 10.  Iron Sucrose: A Wealth of Experience in Treating Iron Deficiency.

Authors:  Iain C Macdougall; Josep Comin-Colet; Christian Breymann; Donat R Spahn; Ioannis E Koutroubakis
Journal:  Adv Ther       Date:  2020-04-15       Impact factor: 3.845

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.